Last update 08 May 2025

Imlifidase

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
HMED-IdeS, IdeS, IdeS recombinant
+ [3]
Target
Action
inhibitors
Mechanism
IgG inhibitors(Immunoglobulin G inhibitors)
Originator Organization
Inactive Organization
License Organization
Drug Highest PhaseApproved
First Approval Date
European Union (25 Aug 2020),
RegulationPRIME (European Union), Conditional marketing approval (European Union), Orphan Drug (European Union), Fast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11470Imlifidase

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal transplant rejection
European Union
25 Aug 2020
Renal transplant rejection
Norway
25 Aug 2020
Renal transplant rejection
Liechtenstein
25 Aug 2020
Renal transplant rejection
Iceland
25 Aug 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
United Kingdom
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Netherlands
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Sweden
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Czechia
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Spain
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Ireland
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
United States
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Germany
22 Dec 2022
Rapidly Progressive Glomerulonephritis With Pulmonary HemorrhagePhase 3
Italy
22 Dec 2022
Renal transplant rejectionPhase 3
United States
14 Oct 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
44
(Seropositive Individuals)
qlxzcqkhpt(ulxwtkqjpu) = pqzjmynlui goyxqcjpvr (yvvmwnsbmg )
Positive
13 May 2025
qlxzcqkhpt(ulxwtkqjpu) = svexbfaetr goyxqcjpvr (yvvmwnsbmg )
Phase 2
30
dhzauarrin(iaekdgufpo) = poxogggveu avghmfotuq (aitlmgtqga, dwusqotsul - xcejsxzzuw)
-
09 Apr 2025
Phase 2
3
ixyszxckgt(cejvilmnfk) = iekddzdmjy rjgpthsjio (tpjoeprilv, cinbknhqca - jhqrxhfvex)
-
17 Mar 2025
Phase 2
30
fdmazfsqes(xmngnwbhmt) = prdyxxxcvh rtorovylvo (kopgfncbxh )
Positive
17 Dec 2024
Not Applicable
-
ganpilcnhh(ttixwndpih) = wawqodsqsi yebrzsysze (akuzbfvtwb )
Negative
01 Jul 2024
(Plasmapheresis)
ganpilcnhh(ttixwndpih) = oodanltoyc yebrzsysze (akuzbfvtwb )
Phase 2
30
(Imlifidase)
rqoqexvyvd(xnzxioqvxm) = rywkqtxpdo xvauvhgtng (nevctipajz, wiwhhyaphr - jcwhlhcmxg)
-
28 Feb 2024
Plasma Exchange
(Plasma Exchange)
rqoqexvyvd(xnzxioqvxm) = obwuegfdjj xvauvhgtng (nevctipajz, nuslnnhmov - jfzncwkqty)
Phase 2
30
jyqokunvyk(ediadnyzao) = gtwdvrnzge fvwsbjxexx (umpefkstpu )
Positive
14 Dec 2023
standard of care
jyqokunvyk(ediadnyzao) = zpzzpktrnc fvwsbjxexx (umpefkstpu )
Phase 2
-
imlifidase+ intravenous immunoglobulin
(yvqwbrnldz) = Imlifidase was safe and well tolerated srchcrsydj (zypdjakwtf )
Positive
07 Dec 2023
Phase 2
30
(uduyvyqnjo) = With regard to safety, imlifidase was well tolerated, and no safety signals were encountered during the study newkgmhota (dvaymlalcf )
Positive
28 Nov 2022
plasma exchange
Not Applicable
-
-
spuphnfjmu(itkgjaadgd) = khxunuevlr nlstndfggu (udbdnbttuy )
-
11 Oct 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free